Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

Shark Tank's Mark Cuban speaks out on weight-loss drugs

A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.

The Street

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic success story: 'Weight-loss drugs, costs and my health'

Ozempic is pricey, but a great health insurance plan paved the way for a software professional to experience dramatic results.

The Street

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Costco enters a controversial industry with its latest move

The retail giant is expanding one of its beloved programs to include a growing trend.

The Street

Read news from The Economist, FT, and more,
with one subscription

Ozempic, weight-loss drugs force a change of focus on health

The effectiveness of weight-loss drugs mean people who take them have more fitness challenges to confront.

The Street

Ozempic, weight-loss drugs rise and the fitness industry reacts

The increasing popularity of GLP-1 medications such as Ozempic triggers some changes.

The Street

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Barchart

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Mark Cuban shares thoughts on Ozempic and his drug company

The Shark Tank billionaire has a question for Novo Nordisk and TheStreet seeks an answer.

Investors Business Daily

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

International Business Times

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

Top News

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

FDA approves Wegovy label change to reduce cardiovascular risk in overweight patients, a significant advancement in obesity treatment with potential implic...

Investors Business Daily

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.